ReviewNutrients2026
Preclinical Evidence and Mechanisms of Traditional Chinese Medicine Polysaccharides Regulating the Gut-Lung Axis via Gut Microbiota in Respiratory Diseases.
Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Traditional Chinese medicine (TCM) polysaccharides are important active components of traditional Chinese medicine, and their anti-inflammatory, immunomodulatory, and mucosal barrier protective effects have attracted widespread attention. Since most traditional Chinese medicine polysaccharides are difficult to be completely digested and absorbed in the gastrointestinal tract, their interventional effects on respiratory diseases may be closely related to the selective utilization by gut microorganisms and the regulation of the gut-lung axis. Therefore, the structural and functional interactions between traditional Chinese medicine polysaccharides and gut microbiota have gradually become an important direction in traditional Chinese medicine pharmacology and microecology research. This review mainly explores two core questions: first, how traditional Chinese medicine polysaccharides that can act on the gut-lung axis drive candidate gut bacteria and metabolic networks; second, how polysaccharide-driven candidate bacteria and metabolic networks regulate pulmonary infection, allergic inflammation, chronic airway injury, and fibrosis through the intestinal mucosal barrier, immune cell reprogramming, and cross-organ signal transmission. Accordingly, this narrative mechanistic review examines selected preclinical studies on traditional Chinese medicine polysaccharides regulating the gut-lung axis, focusing on summarizing the continuous mechanisms by which different polysaccharides promote the proliferation of related microbial communities and metabolite production through selective feeding of gut microorganisms, stabilize intestinal mucosal immunity, and exert pulmonary interventional effects. This review aims to deepen the understanding of the interaction mechanisms among traditional Chinese medicine polysaccharides, microorganisms, and the host, provide some reference for establishing a mechanistic evidence framework for gut-lung axis research and screening potential active polysaccharides with relevant structures and microbiota effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.